Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 237

1.

Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial.

Moulton CA, Gu CS, Law CH, Tandan VR, Hart R, Quan D, Fairfull Smith RJ, Jalink DW, Husien M, Serrano PE, Hendler AL, Haider MA, Ruo L, Gulenchyn KY, Finch T, Julian JA, Levine MN, Gallinger S.

JAMA. 2014 May 14;311(18):1863-9. doi: 10.1001/jama.2014.3740.

PMID:
24825641
2.

Improved long-term survival after resection of colorectal liver metastases following staging with FDG positron emission tomography.

Abbadi RA, Sadat U, Jah A, Praseedom RK, Jamieson NV, Cheow HK, Whitley S, Ford HE, Wilson CB, Harper SJ, Huguet EL.

J Surg Oncol. 2014 Sep;110(3):313-9. doi: 10.1002/jso.23623. Epub 2014 Apr 16.

PMID:
24737685
3.

Effect of chemotherapy on the impact of FDG-PET/CT in selection of patients for surgical resection of colorectal liver metastases: single center analysis of PET-CAM randomized trial.

Metser U, Halankar J, Langer D, Mohan R, Hussey D, Hadas M, Tamir S.

Ann Nucl Med. 2017 Feb;31(2):153-162. doi: 10.1007/s12149-016-1139-y. Epub 2016 Nov 15.

PMID:
27848159
4.

Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT.

Wildi SM, Gubler C, Hany T, Petrowsky H, Clavien PA, Jochum W, Gerlach T, Fried M, Mullhaupt B.

J Clin Ultrasound. 2008 Jan;36(1):20-6.

PMID:
17937421
5.

Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases.

Glazer ES, Beaty K, Abdalla EK, Vauthey JN, Curley SA.

Arch Surg. 2010 Apr;145(4):340-5; discussion 345. doi: 10.1001/archsurg.2010.41.

PMID:
20404283
6.

The role of FDG-PET in the selection of patients with colorectal liver metastases.

Wiering B, Krabbe PF, Dekker HM, Oyen WJ, Ruers TJ.

Ann Surg Oncol. 2007 Feb;14(2):771-9.

PMID:
17086488
7.

Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases.

Joyce DL, Wahl RL, Patel PV, Schulick RD, Gearhart SL, Choti MA.

Arch Surg. 2006 Dec;141(12):1220-6; discussion 1227.

PMID:
17178965
8.

Prognostic value of metabolic parameters in patients with synchronous colorectal cancer liver metastasis following curative-intent colorectal and hepatic surgery.

Lee HS, Kim HO, Hong YS, Kim TW, Kim JC, Yu CS, Kim JS.

J Nucl Med. 2014 Apr;55(4):582-9. doi: 10.2967/jnumed.113.128629. Epub 2014 Feb 18.

9.
11.

Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial.

Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, George S, Mant D; FACS Trial Investigators..

JAMA. 2014 Jan 15;311(3):263-70. doi: 10.1001/jama.2013.285718.

PMID:
24430319
12.

[Use of PET-CT in pre-surgical staging of colorectal cancer hepatic metastases].

Ramos E, Martínez L, Gámez C, Torras J, Valls C, Rafecas A, Lladó L, Jorba R, Ruiz S, Serrano T, Fabregat J.

Cir Esp. 2008 Aug;84(2):71-7. Spanish.

13.

Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery.

Wiering B, Ruers TJ, Krabbe PF, Dekker HM, Oyen WJ.

Ann Surg Oncol. 2007 Feb;14(2):818-26. Epub 2006 Nov 29.

PMID:
17136470
14.

Oncological safety of ultrasound-guided laparoscopic liver resection for colorectal metastases: a case-control study.

Langella S, Russolillo N, D'Eletto M, Forchino F, Lo Tesoriere R, Ferrero A.

Updates Surg. 2015 Jun;67(2):147-55. doi: 10.1007/s13304-015-0325-0. Epub 2015 Jul 29.

PMID:
26220046
15.

Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.

Yao J, Gan G, Farlow D, Laurence JM, Hollands M, Richardson A, Pleass HC, Lam VW.

ANZ J Surg. 2012 Mar;82(3):140-4. doi: 10.1111/j.1445-2197.2011.05972.x. Epub 2012 Jan 17.

PMID:
22510123
16.

Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.

Lastoria S, Piccirillo MC, Caracò C, Nasti G, Aloj L, Arrichiello C, de Lutio di Castelguidone E, Tatangelo F, Ottaiano A, Iaffaioli RV, Izzo F, Romano G, Giordano P, Signoriello S, Gallo C, Perrone F.

J Nucl Med. 2013 Dec;54(12):2062-9. doi: 10.2967/jnumed.113.119909. Epub 2013 Oct 17.

17.

The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.

Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ.

Cancer. 2005 Dec 15;104(12):2658-70. Review.

18.

Liver resection for metastatic colorectal cancer: assessing the risk of occult irresectable disease.

Jarnagin WR, Fong Y, Ky A, Schwartz LH, Paty PB, Cohen AM, Blumgart LH.

J Am Coll Surg. 1999 Jan;188(1):33-42.

PMID:
9915240
19.

Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study.

Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, Pruim J, Dekker HM, Krabbe PF, Oyen WJ.

J Nucl Med. 2009 Jul;50(7):1036-41. doi: 10.2967/jnumed.109.063040. Epub 2009 Jun 12.

20.

PET-CT as a predictor of outcome in resectable colorectal liver metastases.

Jones C, Badger SA, Stevenson M, Diamond T, McKie LD, Taylor MA, Wilson RH, Lynch TB.

Eur J Gastroenterol Hepatol. 2014 Apr;26(4):466-72. doi: 10.1097/MEG.0000000000000036.

PMID:
24445726

Supplemental Content

Support Center